CeQur® Achieves Milestones with FDA Advances for Insulin Delivery
On June 4, 2026, CeQur®, a company specializing in simplifying insulin delivery for diabetes patients, made headlines by announcing two recent FDA clearances for their product, CeQur Simplicity™. The innovative device now has clearance for extended wear of up to seven days and the introduction of a new 1-unit (1U) dosing device. These advancements represent a significant leap forward in insulin management, aiming to ease the daily lives of those living with diabetes.
The FDA's new clearances mark pivotal changes in the way mealtime insulin can be managed. The approval of up to a seven-day wear period for CeQur Simplicity significantly reduces the burden on patients, allowing them to change devices less frequently. Patients have traditionally faced pressure and stress associated with multiple device changes within short time frames, so this change is set to enhance their quality of life. Additionally, the introduction of a 1-unit dosing device provides healthcare professionals with a more precise tool for individualizing insulin regimens. This is particularly beneficial for patients who need tighter control over their glucose levels or have lower insulin requirements during mealtimes.
Bradley Paddock, CEO of CeQur, emphasized that these updates respond directly to valuable feedback received from both physicians and patients. The newly approved enhancements are not merely incremental but expand the population that can effectively be treated with CeQur Simplicity, establishing it as a notable alternative to traditional multiple daily injections.
Furthermore, CeQur will feature two clinical research posters at the upcoming 86th American Diabetes Association (ADA) Scientific Sessions, which will be held from June 5 to June 8, 2026, in New Orleans, Louisiana. The posters will present compelling real-world data derived from a study involving 1,073 adults, showcasing the device’s significant impact on patient experience regarding insulin delivery. The topics of the posters will be:
Healthcare providers attending the conference will have the opportunity to engage with these findings by visiting the posters or CeQur at their dedicated Booth #1205.
CeQur Simplicity™ is designed to be a user-friendly, discreet, and injection-free solution for administering mealtime insulin. Its clinical effectiveness has been demonstrated in improvement of patient A1C levels and achieving time-in-range goals. The product signifies an enormous step forward for individuals living with diabetes, as it addresses numerous challenges related to insulin delivery.
Looking ahead, CeQur hopes that these advancements will help to reshape diabetes management practices, ensuring that more patients gain access to innovative solutions and improved health outcomes. By minimizing the stresses associated with insulin management, CeQur seeks to empower patients in their daily lives, allowing them to enjoy their meals with greater confidence.
For more information about CeQur Simplicity and how it can improve insulin management, interested individuals can visit MyCeQurSimplicity.com or reach out to customer service at 1-888-55-CEQUR.
CeQur® is dedicated to commercializing advanced insulin delivery systems that promote simplicity and adherence to treatment among people with diabetes. With its innovative, wearable devices, CeQur aims to liberate patients from the hassle of conventional insulin injection practices, ensuring better disease management and quality of life.
Recent FDA Clearances
The FDA's new clearances mark pivotal changes in the way mealtime insulin can be managed. The approval of up to a seven-day wear period for CeQur Simplicity significantly reduces the burden on patients, allowing them to change devices less frequently. Patients have traditionally faced pressure and stress associated with multiple device changes within short time frames, so this change is set to enhance their quality of life. Additionally, the introduction of a 1-unit dosing device provides healthcare professionals with a more precise tool for individualizing insulin regimens. This is particularly beneficial for patients who need tighter control over their glucose levels or have lower insulin requirements during mealtimes.
Bradley Paddock, CEO of CeQur, emphasized that these updates respond directly to valuable feedback received from both physicians and patients. The newly approved enhancements are not merely incremental but expand the population that can effectively be treated with CeQur Simplicity, establishing it as a notable alternative to traditional multiple daily injections.
Clinical Evidence at the ADA Conference
Furthermore, CeQur will feature two clinical research posters at the upcoming 86th American Diabetes Association (ADA) Scientific Sessions, which will be held from June 5 to June 8, 2026, in New Orleans, Louisiana. The posters will present compelling real-world data derived from a study involving 1,073 adults, showcasing the device’s significant impact on patient experience regarding insulin delivery. The topics of the posters will be:
- - Poster #1865-P: Advancing Diabetes Care by Simplifying Insulin Delivery
- - Poster #1867-P: Lowering Diabetes Treatment Burden Through a Simple Switch to Insulin Patch Therapy
Healthcare providers attending the conference will have the opportunity to engage with these findings by visiting the posters or CeQur at their dedicated Booth #1205.
Overview of CeQur Simplicity™
CeQur Simplicity™ is designed to be a user-friendly, discreet, and injection-free solution for administering mealtime insulin. Its clinical effectiveness has been demonstrated in improvement of patient A1C levels and achieving time-in-range goals. The product signifies an enormous step forward for individuals living with diabetes, as it addresses numerous challenges related to insulin delivery.
Looking ahead, CeQur hopes that these advancements will help to reshape diabetes management practices, ensuring that more patients gain access to innovative solutions and improved health outcomes. By minimizing the stresses associated with insulin management, CeQur seeks to empower patients in their daily lives, allowing them to enjoy their meals with greater confidence.
For more information about CeQur Simplicity and how it can improve insulin management, interested individuals can visit MyCeQurSimplicity.com or reach out to customer service at 1-888-55-CEQUR.
About CeQur®
CeQur® is dedicated to commercializing advanced insulin delivery systems that promote simplicity and adherence to treatment among people with diabetes. With its innovative, wearable devices, CeQur aims to liberate patients from the hassle of conventional insulin injection practices, ensuring better disease management and quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.